Oppenheimer & Co’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.65M Buy
23,915
+1,689
+8% +$259K 0.04% 411
2025
Q4
$3.06M Sell
22,226
-14,618
-40% -$1.91M 0.04% 424
2025
Q3
$4.72M Sell
36,844
-1,151
-3% -$140K 0.06% 355
2025
Q2
$4.6M Buy
37,995
+1,160
+3% +$131K 0.06% 334
2025
Q1
$4.11M Buy
36,835
+2,308
+7% +$246K 0.06% 334
2024
Q4
$3.36M Buy
34,527
+671
+2% +$71.6K 0.05% 388
2024
Q3
$3.89M Buy
33,856
+1,150
+4% +$130K 0.06% 344
2024
Q2
$3.48M Buy
32,706
+1,768
+6% +$177K 0.06% 361
2024
Q1
$2.99M Sell
30,938
-58
-0.2% -$5.95K 0.05% 404
2023
Q4
$3.13M Buy
30,996
+537
+2% +$51.8K 0.06% 374
2023
Q3
$3.1M Buy
30,459
+45
+0.1% +$4.57K 0.06% 336
2023
Q2
$3.07M Sell
30,414
-646
-2% -$64.6K 0.06% 355
2023
Q1
$2.86M Sell
31,060
-493
-2% -$43.1K 0.06% 355
2022
Q4
$2.86M Sell
31,553
-1,585
-5% -$134K 0.07% 340
2022
Q3
$2.52M Sell
33,138
-1,541
-4% -$128K 0.06% 368
2022
Q2
$2.93M Sell
34,679
-1,393
-4% -$122K 0.06% 355
2022
Q1
$3.17M Buy
36,072
+8,249
+30% +$714K 0.06% 379
2021
Q4
$2.43M Buy
27,823
+371
+1% +$30.8K 0.04% 454
2021
Q3
$2.25M Sell
27,452
-4,846
-15% -$436K 0.04% 475
2021
Q2
$2.95M Sell
32,298
-1,292
-4% -$115K 0.05% 402
2021
Q1
$2.87M Sell
33,590
-5,309
-14% -$476K 0.06% 368
2020
Q4
$3.67M Sell
38,899
-264
-0.7% -$23.1K 0.08% 296
2020
Q3
$3.41M Sell
39,163
-977
-2% -$84.6K 0.09% 271
2020
Q2
$3.51M Sell
40,140
-1,181
-3% -$102K 0.09% 252
2020
Q1
$3.41M Sell
41,321
-573
-1% -$51.1K 0.1% 206
2019
Q4
$3.97M Sell
41,894
-3,119
-7% -$280K 0.1% 227
2019
Q3
$3.91M Buy
45,013
+397
+0.9% +$35.6K 0.11% 214
2019
Q2
$4.07M Sell
44,616
-5,498
-11% -$465K 0.11% 211
2019
Q1
$4.32M Buy
50,114
+8,083
+19% +$649K 0.12% 205
2018
Q4
$3.23M Buy
42,031
+1,117
+3% +$86.9K 0.1% 221
2018
Q3
$3.16M Sell
40,914
-15,764
-28% -$1.17M 0.08% 276
2018
Q2
$3.84M Buy
56,678
+1,440
+3% +$99.4K 0.1% 223
2018
Q1
$4M Buy
55,238
+726
+1% +$55.3K 0.1% 223
2017
Q4
$4.1M Buy
54,512
+97
+0.2% +$7.32K 0.11% 230
2017
Q3
$4.19M Buy
54,415
+3,146
+6% +$238K 0.11% 218
2017
Q2
$3.83M Buy
51,269
+10,380
+25% +$736K 0.11% 242
2017
Q1
$2.72M Sell
40,889
-1,114
-3% -$74.2K 0.08% 304
2016
Q4
$2.74M Sell
42,003
-91
-0.2% -$5.9K 0.08% 295
2016
Q3
$2.98M Sell
42,094
-1,123
-3% -$81.8K 0.09% 267
2016
Q2
$3.19M Sell
43,217
-6,014
-12% -$415K 0.1% 254
2016
Q1
$3.19M Sell
49,231
-9,892
-17% -$673K 0.1% 238
2015
Q4
$4.56M Sell
59,123
-21,980
-27% -$1.75M 0.14% 169
2015
Q3
$6.68M Sell
81,103
-1,789
-2% -$159K 0.2% 112
2015
Q2
$7.3M Buy
82,892
+4,335
+6% +$398K 0.2% 114
2015
Q1
$6.94M Sell
78,557
-70
-0.1% -$6.21K 0.19% 124
2014
Q4
$6.53M Buy
78,627
+6,382
+9% +$529K 0.19% 130
2014
Q3
$6.09M Buy
72,245
+4,749
+7% +$384K 0.18% 136
2014
Q2
$5.48M Sell
67,496
-1,072
-2% -$84.3K 0.16% 141
2014
Q1
$5.22M Buy
68,568
+5,008
+8% +$365K 0.16% 152
2013
Q4
$4.58M Buy
63,560
+1,053
+2% +$73.2K 0.15% 175
2013
Q3
$4.3M Buy
62,507
+2,060
+3% +$136K 0.15% 176
2013
Q2
$3.83M Buy
+60,447
New +$3.93M 0.15% 174

Other funds holding NVS

Oppenheimer & Co's NVS Position: Q1 2026 in Review

Oppenheimer & Co increased its Novartis (NVS) stake by 7.6% in Q1 2026, buying an estimated $259K and bringing the position to 23,915 shares worth $3.65M. The position accounts for 0.04% of the portfolio, ranked #411.

Oppenheimer & Co first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.3M in Q2 2015. 1,592 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Oppenheimer & Co held 23,915 shares of Novartis worth $3.65M as of Q1 2026.
  • Oppenheimer & Co bought 1,689 Novartis shares in Q1 2026, an estimated $259K.
  • Novartis made up 0.04% of Oppenheimer & Co's portfolio in Q1 2026, its #411 holding.
  • Oppenheimer & Co first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • Oppenheimer & Co's Novartis position peaked at $7.3M in Q2 2015.
  • 1,592 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.